Spanish Pharma Falls 1.1% on the Stock Market in First Quarter Despite Pharma Mar’s Resilience

Spanish pharmaceutical companies listed on the continuous market closed the first quarter in the red. The aggregate capitalization of Grifols, Almirall, Rovi, Faes Farma, Pharma Mar, and Reig Jofre fell by 1.1% between January and March.

The performance of the pharmaceutical sector in the first quarter was better than that of the Ibex35, the Spanish benchmark index, which fell by 3% between January and March, impacted by the rise in inflation, interest rate policies, and the Russian invasion of Ukraine. In fact, the Ibex35 stocks that performed best in March were pharmaceuticals and banking, with special attention to Pharma Mar, boosted by its results and its star drug Zepzelca, indicated for the treatment of metastatic small-cell lung cancer.

The six listed pharmaceutical companies closed the first quarter with a stock market value of $16.7 billion (€15.1 billion), compared to $17.4 billion (€15.7 billion) at the end of the previous quarter. This decrease was due to the performance of Grifols and Rovi.

Find more about the economic situation of the most important Spanish pharma companies and read the latest financial news with the Born2Invest mobile app.

The six listed Spanish pharma companies closed the first quarter of 2022 with a stock market value of $16.7 billion (€15.1 billion)

The biggest decline was registered by Rovi. The pharmaceutical company’s shares corrected by 8.9% in the period, to $74.3 (€67.2)per share. The López-Belmonte family, the first shareholder of the pharmaceutical company, sold in mid-March, through its investment vehicle Norbel Inversiones, 5% of the company for $199 million (€180.1 million). This is one of the facts that justify this decline in the stock market. In fact, Rovi’s shares plummeted almost 9% at the moment of announcing the sale.

The other fall was recorded by Grifols. The Catalan pharmaceutical company’s shares fell by 2.3% to $18.23 (€16.48). Nevertheless, Grifols continues to be the pharmaceutical company with the largest capitalization, with more than $7.7 billion (€7 billion).

Grifols, which specializes in the production of plasma derivatives, closed 2021 with a profit of $201.6 million (€182.3 million), compared to the $684 million (€618.5 million) recorded in 2020, according to the latest results published by the company. The company attributes this result to “the impact of Covid-19.”

Pharma Mar shares rose 20% at the end of March

The largest increase was for Pharma Mar. The pharmaceutical company’s shares rose 20% at the end of March, to $75.6 (€68.4) per share. However, it still has some way to go compared to the levels above $110.6 (€100) per share that it reached a year ago. Pharma Mar is followed by Faes Farma.

The pharmaceutical company’s shares rose to $4.06 (€3.67) per share, up 5.5% compared to the previous quarter. Last week, the company held a meeting with analysts and investors in which it advanced earnings estimates for 2022, expecting to achieve a net profit of between $98.5 million (€89 million) and $102.9 (€93 million), between 7.2% and 12% more than in 2021.

Reig Jofre posted a 2.76% increase to $3.65 (€3.3) per share, while Almirall achieved a 2% increase to $12.7 (€11.5) per share. The company, which owns Almax, rose 6.5% in the stock market on February 21st, after announcing a generational change in its chairmanship.

Carlos Gallardo, son of the current chairman, Jorge Gallardo, will take over as chairman of the board of directors. Jorge Gallardo is stepping down due to his retirement. The resignation will become effective after Almirall’s General Shareholders’ Meeting, which will take place on May 6th. As a consequence of this decision, Jorge Gallardo leaves the presidency of the company, to which he has dedicated more than fifty years.

__

(Featured image by 3844328 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.